Upstream use of small-molecule glycoprotein IIb/IIIa inhibitors in patients with non-ST-segment elevation acute coronary syndromes a systematic overview of randomized clinical trials

Circulation: Cardiovascular Quality and Outcomes

Volumn 4, Issue 4, 2011, Pages 448-458

  Tricoci, Pierluigi ^a   Newby, L Kristin ^a   Hasselblad, Vic ^a   Kong, David F ^a   Giugliano, Robert P ^b   White, Harvey D ^c   Théroux, Pierre ^d   Stone, Gregg W ^e   Moliterno, David J ^f   Van De Werf, Frans ^g   Armstrong, Paul W ^h   Prabhakaran, Dorairaj ⁱ   Rasoul, Saman ^j   Bolognese, Leonardo ^k   Durand, Eric ^l   Braunwald, Eugene ^b   Califf, Robert M ^m   Harrington, Robert A ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d MONTREAL HEART INSTITUTE   (Canada)

^e NewYork Presbyterian Hospital   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ Center for Chronic Disease Control   (India)

^j Isala klinieken ^*  (Netherlands)

^k IRCCS POLICLINICO SAN DONATO   (Italy)

^l UNIVERSITÉ PARIS DESCARTES   (France)

^m DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Bleeding; Glycoprotein IIb IIIa inhibitors; Meta analysis; Non ST segment elevation acute coronary syndromes

Indexed keywords

ABCIXIMAB; DALTEPARIN; EPTIFIBATIDE; HEPARIN; LAMIFIBAN; PLACEBO; THIENOPYRIDINE DERIVATIVE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; BLOOD TRANSFUSION; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; MORTALITY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; NON ST SEGMENT ELEVATION CORONARY ARTERY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

ACETATES; ACUTE CORONARY SYNDROME; ADMINISTRATION, CUTANEOUS; ANGIOPLASTY; ELECTROCARDIOGRAPHY; HEMORRHAGE; HUMANS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SURVIVAL ANALYSIS; TYROSINE;

EID: 80054767005     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.110.960294     Document Type: Review

References (41)

1. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Chavey WE, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2007 guidelines for the management of patients with unstable angina/NSTEMI. J Am Coll Cardiol. 2007;50:e1-e157
2. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández- Avilés F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of NSTE ACS. Eur Heart J. 2007;28:1598-1660
3. CURE Investigators. Effects of clopidogrel in addition to aspirin in patients with ACS without ST-segment elevation. N Engl J Med. 2001; 345:494-502
4. ACUITY Investigators. Bivalirudin for patients with ACS. N Engl J Med. 2006;355:2203-2216
5. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with ACS. N Engl J Med. 2007;357:2001-2015
6. PLATO Investigators. Ticagrelor versus clopidogrel in patients with ACS. N Engl J Med. 2009;361:1045-1057
7. EARLY ACS Investigators. Early versus delayed, provisional eptifibatide in ACS. N Engl J Med. 2009;360:2176-2190
8. ACUITY Investigators. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in ACS. JAMA. 2007;297:591-602
9. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, Knipschild PG. The Delphi list: A criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol. 1998;51:1235-1241 (Pubitemid 29009523)
10. Rao SV, Eikelboom J, Steg PG, Lincoff AM, Weintraub WS, Bassand JP, Rao AK, Gibson CM, Petersen JL, Mehran R, Manoukian SV, Charnigo R, Lee KL, Moscucci M, Harrington RA. Standardized reporting of bleeding complications for clinical investigations in ACS: A proposal from the Academic Bleeding Consensus Multidisciplinary Working Group. Am Heart J. 2009;158:881-886
11. Hedges L, Olkin I. Statistical Methods for Meta-Analysis. Orlando, FL: Academic Press; 1985
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188 (Pubitemid 17189972)
13. Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, Nasmith J, Fung AY, Boudreault JR, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: The Canadian Lamifiban Study. Circulation. 1996;94:899-905 (Pubitemid 26292838)
14. PRISM Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498-1505
15. PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave MI. N Engl J Med. 1998;338:1488-1497
16. PARAGON Investigators. International, randomized, controlled trial of lamifiban, heparin, or both in unstable angina. Circulation. 1998;97: 2386-2395
17. PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with ACS. N Engl J Med. 1998;339:436-443
18. Randomized, placebo-controlled trial of titrated intravenous lamifiban for ACS. Circulation. 2002;105:316-321
19. Kim JH, Jeong MH, Rhew JY, Lim JH, Yun KH, Kim KH, Kang DK, Hong SN, Lim SY, Lee SH, Lee YS, Hong YJ, Park HW, Kim W, Ahn YK, Moon Y, Cho JG, Park JC, Kang JC. Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low-molecularweight heparin in patients with ACS. Circ J. 2005;69:159-164 (Pubitemid 40313034)
20. Bolognese L, Falsini G, Liistro F, Angioli P, Ducci K, Taddei T, Tarducci R, Cosmi F, Baldassarre S, Burali A. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk ACS treated with PCI. J Am Coll Cardiol. 2006;47:522-528 (Pubitemid 43170839)
21. ELISA Study Group. Routine upstream versus selective downstream use of tirofiban in NSTEMI patients scheduled for early invasive therapy. J Thromb Thrombolysis. 2007;24:241-246
22. Durand E, Hamm CW, Macaya CM, Georges JL, Coste P, Wolf JE, Slama MS, Husted SE, Mosseri M, Lafont A. A randomised controlled trial of upstream administration of eptifibatide in patients presenting NSTE ACS treated with an invasive strategy. EuroIntervention. 2007;3: 228-234
23. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE, Steward DE, Theroux P, Alpert JS, Eagle KA, Faxon DP, Fuster V, Gardner TJ, Gregoratos G, Russell RO, Smith SC. ACC/AHA guidelines for the management of patients with unstable angina and NSTEMI. J Am Coll Cardiol. 2000;36:970-1062
24. Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P, Van de Werf F, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa inhibitors in ACS: A meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189-198 (Pubitemid 34113814)
25. Newby LK, Ohman EM, Christenson RH, Moliterno DJ, Harrington RA, White HD, Armstrong PW, Van De Werf F, Pfisterer M, Hasselblad V, Califf RM, Topol EJ. Benefit of glycoprotein IIb/IIIa inhibition in patients with ACS and troponin T-positive status. Circulation. 2001;103: 2891-2896
26. Heeschen C, van Den Brand MJ, Hamm CW, Simoons ML. Angiographic findings in patients with refractory unstable angina according to troponin T status. Circulation. 1999;100:1509-1514 (Pubitemid 29461462)
27. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, Hamm CW, Moliterno DJ, Califf RM, White HD, Kleiman NS, Théroux P, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with NSTE ACS. Circulation. 2001;104:2767-2771 (Pubitemid 33126648)
28. Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after PCI. J Am Coll Cardiol. 2003;41:26-32 (Pubitemid 36044399)
29. Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, Tcheng JE, Lincoff AM, Hasselblad V, Topol EJ. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 1998;98:2829-2835 (Pubitemid 29003963)
30. Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor inhibition in NSTE ACS: Early benefit during medical treatment only, with additional protection during PCI. Circulation. 1999;100:2045-2048 (Pubitemid 29532053)
31. TIMI Study Group. Association between duration of tirofiban therapy before percutaneous intervention and tissue-level perfusion. Am J Cardiol. 2004;94:492-494
32. NRMI 4 Investigators. Early use of glycoprotein IIb/IIIa inhibitors in NSTEMI. J Am Coll Cardiol. 2003;42:45-53
33. Tricoci P, Peterson ED, Chen AY, Newby LK, Harrington RA, Greenbaum AB, Cannon CP, Gibson CM, Hoekstra JW, Pollack CV, Ohman EM, Gibler WB, Roe MT. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with NSTEMI undergoing PCI. Am J Cardiol. 2007;99:1389-1393
34. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schömig A, Kastrati A. Periprocedural bleeding and 1-year outcome after PCI: Appropriateness of including bleeding as a component of a quadruple endpoint. J Am Coll Cardiol. 2008;51:690-697 (Pubitemid 351221218)
35. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, Moliterno DJ, Lindblad L, Pieper K, Topol EJ, Stamler JS, Califf RM. Relationship of blood transfusion and clinical outcomes in patients with ACS. JAMA. 2004;292:1555-1562 (Pubitemid 39314961)
36. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, Mahaffey KW, Califf RM, Harrington RA. Impact of bleeding severity on clinical outcomes among patients with ACS. Am J Cardiol. 2005;96: 1200-1206 (Pubitemid 41505393)
37. Unger EF. Weighing benefits and risks: The FDA's review of prasugrel. N Engl J Med. 2009;361:942-945
38. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML. Predictors of outcome in patients with ACS without persistent ST-segment elevation. Circulation. 2000;101:2557-2567
39. Antman EM, Cohen M, Bernink PJLM, McCabe CH, Horacek T, Papuchis G, Mautner B, Corbalan R, Radley D, Braunwald E. The TIMI risk score for unstable angina/NSTEMI: A method for prognostication and therapeutic decision-making. JAMA. 2000;284:835-842 (Pubitemid 30643610)
40. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, Wang TY, Gibler WB, Ohman EM, Roe MT, Pollack CV, Peterson ED, Alexander KP. Baseline risk of major bleeding in NSTEMI: CRUSADE bleeding score. Circulation. 2009;119:1873-1882
41. GRACE Investigators. A validated prediction model for all forms of ACS: Estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291:2727-2733.